CA2751641C - Antibacterial phage, phage peptides and methods of use thereof - Google Patents

Antibacterial phage, phage peptides and methods of use thereof Download PDF

Info

Publication number
CA2751641C
CA2751641C CA2751641A CA2751641A CA2751641C CA 2751641 C CA2751641 C CA 2751641C CA 2751641 A CA2751641 A CA 2751641A CA 2751641 A CA2751641 A CA 2751641A CA 2751641 C CA2751641 C CA 2751641C
Authority
CA
Canada
Prior art keywords
seq
bacteriophage
pharmaceutical composition
infection
nucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2751641A
Other languages
English (en)
French (fr)
Other versions
CA2751641A1 (en
Inventor
Miguel Angelo Da Costa Garcia
Carlos Jorge Sousa De Sao Jose
Clara Isabel Rodrigues Leandro
Filipa Maria Rodrigues Pardal Dias Antunes Marcal Da Silva
Sara Ferreira Llorente Grancho Lourenco
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Technophage Investigacao e Desenvolvimento em Biotecnologia SA
Tecnifar Industria Tecnica Farmaceutica SA
Original Assignee
Technophage Investigacao e Desenvolvimento em Biotecnologia SA
Tecnifar Industria Tecnica Farmaceutica SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technophage Investigacao e Desenvolvimento em Biotecnologia SA, Tecnifar Industria Tecnica Farmaceutica SA filed Critical Technophage Investigacao e Desenvolvimento em Biotecnologia SA
Priority to CA3019013A priority Critical patent/CA3019013C/en
Publication of CA2751641A1 publication Critical patent/CA2751641A1/en
Application granted granted Critical
Publication of CA2751641C publication Critical patent/CA2751641C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
CA2751641A 2009-02-06 2010-02-05 Antibacterial phage, phage peptides and methods of use thereof Active CA2751641C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3019013A CA3019013C (en) 2009-02-06 2010-02-05 Antibacterial phage, phage peptides and methods of use thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15058509P 2009-02-06 2009-02-06
US61/150,585 2009-02-06
US21834509P 2009-06-18 2009-06-18
US61/218,345 2009-06-18
PCT/PT2010/000003 WO2010090542A2 (en) 2009-02-06 2010-02-05 Antibacterial phage, phage peptides and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3019013A Division CA3019013C (en) 2009-02-06 2010-02-05 Antibacterial phage, phage peptides and methods of use thereof

Publications (2)

Publication Number Publication Date
CA2751641A1 CA2751641A1 (en) 2010-08-12
CA2751641C true CA2751641C (en) 2018-11-13

Family

ID=42244489

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3019013A Active CA3019013C (en) 2009-02-06 2010-02-05 Antibacterial phage, phage peptides and methods of use thereof
CA2751641A Active CA2751641C (en) 2009-02-06 2010-02-05 Antibacterial phage, phage peptides and methods of use thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA3019013A Active CA3019013C (en) 2009-02-06 2010-02-05 Antibacterial phage, phage peptides and methods of use thereof

Country Status (13)

Country Link
US (2) US9134312B2 (enExample)
EP (3) EP3650034B1 (enExample)
JP (3) JP5701777B2 (enExample)
CN (2) CN102348460B (enExample)
AU (1) AU2010211456B2 (enExample)
BR (1) BRPI1008663B8 (enExample)
CA (2) CA3019013C (enExample)
ES (2) ES2761835T3 (enExample)
PL (1) PL3650034T3 (enExample)
PT (1) PT3115054T (enExample)
RU (2) RU2580248C9 (enExample)
SG (3) SG10201602330VA (enExample)
WO (1) WO2010090542A2 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0607798D0 (en) * 2006-04-20 2006-05-31 Alligator Bioscience Ab Novel polypeptides and use thereof
CA2984933C (en) * 2008-07-03 2020-07-07 The Rockefeller University A chimeric bacteriophage lysin with activity against staphylococci bacteria
AU2010212280B2 (en) * 2009-08-12 2015-09-24 Buddhist Tzu Chi Medical Foundation Phage of acinetobacter Baumannii
PT104837A (pt) 2009-11-24 2011-05-24 Technophage Investiga O E Desenvolvimento Em Biotecnologia S A P?ptidos de fagos enteroc?cicos e m?todos para a sua utiliza??o
EP3443970B1 (en) 2010-09-17 2020-09-09 Tecnifar-Indústria Técnica Farmacêutica, S.A. Antibacterial phage, phage peptides and methods of use thereof
KR101279780B1 (ko) 2011-10-05 2013-06-28 주식회사 인트론바이오테크놀로지 액티노바실러스 플루로뉴모니애에 대한 사멸능을 갖는 박테리오파지
BR112014023321B1 (pt) 2012-03-19 2022-06-14 Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa Composições compreendendo fagos antibacterianos e seus usos
EP3656390B1 (en) * 2012-05-04 2023-10-18 Armata Pharmaceuticals, Inc. Therapeutic bacteriophage compositions
EP2865383A1 (en) * 2013-10-25 2015-04-29 Pherecydes Pharma Phage therapy of pseudomonas infections
US9029319B1 (en) * 2014-08-04 2015-05-12 Centaur, Inc. Water buffalo derived peptide antibiotic therapies
WO2016098116A1 (en) * 2014-12-17 2016-06-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Phage therapy for targeting enterococci
CN105294840B (zh) * 2015-11-20 2018-08-17 深圳市南山区人民医院 一种用于预防和治疗肠致病大肠杆菌感染的肽段
US20170157186A1 (en) * 2015-12-02 2017-06-08 Smart Phage, Inc. Phage to treat bacteria on skin
CN105648109B (zh) * 2016-01-08 2019-04-09 河南医学高等专科学校 一种噬菌体灭菌时化学抗菌剂筛选方法
CN106699862B (zh) * 2016-11-22 2020-06-09 中国科学院海洋研究所 三种来源于脊尾白虾alf的环状多肽及其应用和抗菌剂
CN110691603B (zh) * 2016-12-05 2024-01-30 抗菌技术生物技术研究与发展股份有限公司 包含呼吸道抗菌噬菌体的噬菌体组合物及其使用方法
JP7307681B2 (ja) * 2017-02-17 2023-07-12 カムリス インターナショナル インコーポレイテッド 汎用性抗毒素
KR101957266B1 (ko) * 2017-02-22 2019-03-13 주식회사 인트론바이오테크놀로지 엔테로코쿠스 패슘에 대하여 용균력을 가지는 신규한 항균단백질 efal-2
CN107365363B (zh) * 2017-09-20 2020-08-04 苏州大学 小分子多肽及其应用
CN107827955B (zh) * 2017-11-21 2020-05-29 苏州大学 源于分枝杆菌噬菌体多肽的衍生肽及其应用
KR20200098615A (ko) 2017-12-12 2020-08-20 콘트라펙트 코포레이션 사람 혈청의 존재하에 슈도모나스 아에루기노사에 대해 살균 활성을 갖는 리신 및 이의 유도체
JP7289538B2 (ja) * 2018-03-12 2023-06-12 国立大学法人高知大学 新規バクテリオファージおよび細菌性眼内炎治療剤
WO2019224941A1 (ja) * 2018-05-23 2019-11-28 国立大学法人九州大学 食中毒細菌のバクテリオファージ耐性化抑制剤及びその使用
KR102131692B1 (ko) * 2018-09-11 2020-07-08 경북대학교 산학협력단 병원성 세균을 효과적으로 사멸시키는 재조합 항균 효소 LysSAP26의 용도
RU2703043C1 (ru) * 2018-09-20 2019-10-15 Наталия Петровна Антонова Литический фермент бактериофага и антибактериальная композиция на его основе
KR102193495B1 (ko) * 2018-12-26 2020-12-22 주식회사 옵티팜 신규한 아시네토박터 바우마니 균 특이 박테리오파지 ab63 및 이를 포함하는 항균 조성물
AU2020256258A1 (en) * 2019-04-05 2021-11-04 Contrafect Corporation Lysins and derivatives thereof with bactericidal activity against Pseudomonas aeruginosa, in the presence of human serum
US20220211604A1 (en) * 2019-04-09 2022-07-07 Conopco, Inc., D/B/A Unilever Antimicrobial composition for selective lysis of s. hominis bacteria
WO2020254967A1 (en) * 2019-06-17 2020-12-24 Phagelux Canada Inc. Bacterial control through dispersion of bacteriophage powders
RU2717435C1 (ru) * 2019-06-28 2020-03-23 Акционерное общество "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Штамм бактериофага Pseudomonas aeruginosa N 326 (500320), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов
RU2717451C1 (ru) * 2019-06-28 2020-03-23 Акционерное общество "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Штамм бактериофага Pseudomonas aeruginosa N 323 (500317), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов
RU2717022C1 (ru) * 2019-06-28 2020-03-17 Акционерное общество "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Штамм бактериофага Pseudomonas aeruginosa N 328 (500322), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов
RU2717973C1 (ru) * 2019-06-28 2020-03-27 Акционерное общество "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Штамм бактериофага Pseudomonas aeruginosa N 322 (500316), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов
RU2717026C1 (ru) * 2019-06-28 2020-03-17 Акционерное общество "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Штамм бактериофага Pseudomonas aeruginosa N 325 (500319), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов
RU2717420C1 (ru) * 2019-06-28 2020-03-23 Акционерное общество "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Штамм бактериофага Pseudomonas aeruginosa N 327 (500321), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов
RU2717972C1 (ru) * 2019-06-28 2020-03-27 Акционерное общество "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Штамм бактериофага Pseudomonas aeruginosa N 324 (500318), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов
CN110499266B (zh) * 2019-08-05 2021-04-27 昆明理工大学 一株粪肠球菌及其应用
US20210187046A1 (en) 2019-12-19 2021-06-24 Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa Cocktail compositions comprising respiratory antibacterial phages and methods of use thereof
CN113214364B (zh) * 2020-01-21 2022-11-22 天津大学 一种多重耐药鲍曼不动杆菌识别元件的挖掘与验证
US20230077209A1 (en) * 2020-02-14 2023-03-09 William Colton Bacteriophage Cocktail-Containing Hydrogel Compositions and Methods of Production and Use Thereof
KR102604590B1 (ko) * 2020-09-28 2023-11-23 경북대학교 산학협력단 아시네토박터 바우마니에 대한 사멸능을 가지는 박테리오파지 및 이를 포함하는 조성물
CN116514934B (zh) * 2021-03-04 2024-04-30 西部(重庆)科学城种质创制大科学中心 抗CRISPR-Cas蛋白AcrIIIA1IME1367及其应用
WO2023113396A1 (ko) * 2021-12-14 2023-06-22 경북대학교 산학협력단 클로스트리듐 디피실 세균을 효과적으로 사멸시키는 재조합 항균 단백질의 용도
CN114703173B (zh) * 2022-03-18 2023-06-06 福建省农业科学院农业质量标准与检测技术研究所 一种λ噬菌体DNA提取试剂盒及提取方法
CN114807106B (zh) * 2022-04-25 2023-09-01 昆明市延安医院 一种裂解酶pEf51和穿孔素蛋白pEf191的应用
EP4626449A1 (en) * 2022-11-28 2025-10-08 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Acinetobacter baumannii phages
AU2024272675A1 (en) * 2023-05-17 2025-11-27 Jumpei FUJIKI Phage therapy for alcohol-associated hepatitis
CN118109445A (zh) * 2024-03-22 2024-05-31 广西中医药大学 一种耐甲氧西林金黄色葡萄球菌噬菌体裂解酶LysLP-122及其制备方法和应用
DE102024113842A1 (de) 2024-05-16 2025-11-20 bifa Umweltinstitut GmbH Verfahren zur Verringerung der bakteriellen Last auf bzw. in einer Klimaanlage
CN119162119B (zh) * 2024-07-09 2025-09-05 深圳先进技术研究院 Kl2型鲍曼不动杆菌噬菌体及其筛选方法、噬菌体组合物及应用与药物
CN118787727B (zh) * 2024-08-26 2025-03-11 中国科学院南海海洋研究所 一种清除铜绿假单胞菌的多肽及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5863560A (en) 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
GB9712663D0 (en) * 1997-06-16 1997-08-20 Borealis As Process
US20060292135A1 (en) * 1997-10-31 2006-12-28 Lawrence Loomis Use of bacterial phage-associated lysing proteins for preventing and treating bacterial infections in humans, animals and fowl
WO2000069269A1 (en) * 1999-05-13 2000-11-23 Exponential Biotherapies, Inc. Strains of bacteriophage useful for rescuing patients infected with vancomycin-resistant enterococcus faecium
WO2001050872A2 (en) 2000-01-11 2001-07-19 Intralytix, Inc. Method for produce sanitation using bacteriophages
RU2186574C1 (ru) * 2001-01-24 2002-08-10 Яфаев Рауэль Хасанянович Препарат поливалентного бактериофага против синегнойной палочки, штаммы бактериофага bacteriophagum pseudomonas aeruginosa спбгма им. и.и. мечникова №05, №03, №06 и №07, используемые при приготовлении поливалентного препарата против синегнойной палочки
CN1643139A (zh) * 2002-03-25 2005-07-20 沃里克大学 抗菌剂
US7588929B2 (en) * 2002-12-09 2009-09-15 Phage Biopharm Llc Production of bacteriophage compositions for use in phage therapy
CN101003793A (zh) * 2007-01-11 2007-07-25 中国人民解放军第三军医大学 噬菌体对环境中致病菌的净化技术
PL215522B1 (pl) 2008-09-29 2013-12-31 Inst Immunologii I Terapii Doswiadczalnej Pan Nowe szczepy bakteriofagów do leczenia zakazen bakteryjnych, zwlaszcza szczepami bakterii lekoopornych rodzaju Enterococcus
CA2739717A1 (en) 2008-10-10 2010-04-15 Lusomedicamenta, S.A. Antibacterial phage peptides and methods of use thereof
KR20100093626A (ko) 2009-02-17 2010-08-26 서강대학교산학협력단 슈도모나스 애루지노사에 대한 파아지 치료
PT104837A (pt) 2009-11-24 2011-05-24 Technophage Investiga O E Desenvolvimento Em Biotecnologia S A P?ptidos de fagos enteroc?cicos e m?todos para a sua utiliza??o

Also Published As

Publication number Publication date
RU2014127987A (ru) 2016-02-10
BRPI1008663B1 (pt) 2021-01-05
WO2010090542A3 (en) 2010-12-23
CN105456300B (zh) 2019-07-09
PT3115054T (pt) 2019-12-16
SG2014012611A (en) 2014-07-30
ES2761835T3 (es) 2020-05-21
CA3019013A1 (en) 2010-08-12
JP2012517225A (ja) 2012-08-02
PL3650034T3 (pl) 2024-03-04
SG10201602330VA (en) 2016-04-28
BRPI1008663B8 (pt) 2021-10-05
HK1166956A1 (zh) 2012-11-16
BRPI1008663A2 (pt) 2016-03-08
CA2751641A1 (en) 2010-08-12
RU2580248C9 (ru) 2018-01-17
US9682110B2 (en) 2017-06-20
US20120052048A1 (en) 2012-03-01
JP2017158568A (ja) 2017-09-14
JP5701777B2 (ja) 2015-04-15
SG173533A1 (en) 2011-10-28
WO2010090542A2 (en) 2010-08-12
JP6355792B2 (ja) 2018-07-11
CN105456300A (zh) 2016-04-06
RU2671110C2 (ru) 2018-10-29
CN102348460B (zh) 2015-08-26
AU2010211456B2 (en) 2016-05-26
US9134312B2 (en) 2015-09-15
JP2015154771A (ja) 2015-08-27
RU2580248C2 (ru) 2016-04-10
EP3115054A1 (en) 2017-01-11
EP3650034B1 (en) 2023-09-20
AU2010211456A1 (en) 2011-08-25
ES2963904T3 (es) 2024-04-03
JP6177264B2 (ja) 2017-08-09
EP3115054B1 (en) 2019-11-20
EP2393502B1 (en) 2016-08-31
EP2393502A2 (en) 2011-12-14
CN102348460A (zh) 2012-02-08
US20160022747A1 (en) 2016-01-28
RU2011134315A (ru) 2013-03-20
CA3019013C (en) 2020-12-15
EP3650034C0 (en) 2023-09-20
EP3650034A1 (en) 2020-05-13

Similar Documents

Publication Publication Date Title
CA2751641C (en) Antibacterial phage, phage peptides and methods of use thereof
US9737579B2 (en) Antibacterial phage, phage peptides and methods of use thereof
AU2017204331A1 (en) Antibacterial phage, phage peptides and methods of use thereof
AU2015255318B2 (en) Antibacterial phage, phage peptides and methods of use thereof
HK1166956B (en) Antibacterial phage, phage peptides and methods of use thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150203